Moderna’s experimental coronavirus vaccine gets FDA’s ‘fast track’ status

(Reuters) – Moderna Inc said on Tuesday its experimental coronavirus vaccine had gained the U.S. Food and Drug Administration’s “fast track” designation.

The agency’s fast track status is designed to expedite the review of treatments and vaccines meant for serious conditions.

Reporting by Manas Mishra in Bengaluru; Editing by Amy Caren Daniel

View original article here Source

Related Posts